FACS was used next to quantitatively assess activation and inhibitory markers expressed on CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) (gating strategy outlined in Supplementary Fig. 3A, B). The gene discussed is CD8A; the disease is neoplasm.